News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crown Bioscience, Inc. Adds Former Distinguished Eli Lilly and Company (LLY) Scholar, Dr. Chuan (Joe) Shih to its Senior Management Team


3/3/2010 1:17:14 PM

SANTA CLARA, CA.--(BUSINESS WIRE)—, March 1st, 2010--Crown Biosciences, Inc., a preclinical oncology CRO, announced today that Dr. Chuan (Joe) Shih has accepted the position of Executive Vice President, Integrated Drug Discovery Services Business Unit.

Prior to joining Crown, Dr. Joe Shih, Ph.D., was a Distinguished Lilly Scholar of Discovery Chemistry Research and Technology at Lilly Research Laboratories (LRL), a Division of Eli Lilly and Company. Joe received a doctorate in Organic Chemistry from The Ohio State University in 1982. He was also awarded a Bachelor of Science in Chemistry from the National Chung-Hsing University, Taiwan in 1976, and a Master of Science in Organic Chemistry from The Ohio State University in 1979. Dr. Shih completed a postdoctoral fellowship at Harvard University under Nobel Laureate Professor E. J. Corey from 1982 to 1984. Following his postdoctoral studies, he joined Lilly as a Senior Organic Chemist in 1984. He was promoted to Research Scientist in 1989, to Senior Research Scientist in 1993, to Research Advisor in 1999, to Distinguished Research Fellow in 2004 and to Distinguished Lilly Scholar in 2007.

During his tenure at Eli Lilly, Dr. Shih has distinguished himself as a premier drug hunter by contributing to many LRL oncology drug discovery efforts. Through his collaboration with Princeton University, Dr. Shih contributed to the successful antifolate drug discovery program that has led to the development of ALIMTA®, a blockbuster anticancer agent approved by various regulatory agencies around the globe for the treatment of mesothelioma and non-small cell lung cancer. Dr Shih is a co-inventor of ALIMTA® and a pioneer in the elucidation of the unique "multi-targeted antifolate" mechanism of action of ALIMTA®. Dr. Shih was awarded the 2006 American Chemical Society “Heroes of Chemistry” Award for his role in the discovery and development of ALIMTA®.

Dr. Shih was also instrumental in leading various medicinal chemistry and drug discovery initiatives and efforts in the identification of several novel anticancer agents currently in the Lilly Oncology pipeline. Dr. Shih is widely recognized for his expertise in cancer and medicinal chemistry research. He is frequently invited to lecture and chair sessions at national and international meetings. Dr. Shih has authored and co-authored more than 180 scientific publications and presentations and holds numerous patents. Dr. Shih is also holding a position of visiting Distinguished Chair Professor of Pharmaceutical Sciences at the Department of Applied Biology and Chemical Technology of The Hong Kong Polytechnic University.

"Dr. Shih is widely regarded as one of the industry's leading experts in oncology drug discovery and development. He will bring a unique perspective to the company as we continue to identify new opportunities that help our clients accelerate their drug discovery and development programs," said Alex Wu, Chief Executive Officer of CrownBio.

"CrownBio’s reputation for scientific and service excellence, consistent quality and commitment to supporting the discovery of anti-tumor therapeutics is unparalleled in the industry," said Dr. Shih. "I look forward to working with this truly talented team as well as playing a role in the Company's growth."

About Crown Bioscience Inc.

Crown Bioscience, Inc. is a U.S.-based drug discovery service company with R&D facilities in China committed to advancing anti-cancer therapeutics through the preclinical and drug development stages. Its proprietary CrystalClearTM , HuPrime™ and HuKemia™ platforms enable unique lead optimization and translational oncology strategies to deliver better clinical candidates. Our multi-disciplinary team of experts provides an integrated service solution from your idea to your IND, including: preclinical, translational, and clinical capabilities.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES